<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND/AIMS: Human <z:mp ids='MP_0001265'>runt</z:mp>-related transcription factor 3 (RUNX3) gene was a new candidate <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> suppressor gene involved in the TGF-Î² signaling pathway </plain></SENT>
<SENT sid="1" pm="."><plain>We evaluated the diagnostic role of RUNX3 gene methylation in serum DNA of esophageal <z:hpo ids='HP_0002860'>squamous cell carcinoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESCC</z:e>), <z:hpo ids='HP_0012126'>gastric cancer</z:hpo> (GC) and <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>) patients </plain></SENT>
<SENT sid="2" pm="."><plain>METHODOLOGY: Methylation-specific polymerase chain reaction (MSP) was used to determine the promoter methylation status of RUNX3 gene in serum DNA </plain></SENT>
<SENT sid="3" pm="."><plain>The combination of RUNX3 hypermethylation and conventional <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> markers was further analyzed </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Hypermethylation of RUNX3 was detected in 51.4% (36/70) of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESCC</z:e>, 45.2% (28/62) of GC and 41.5% (27/65) of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> patients, which was significantly higher than that of benign <z:e sem="disease" ids="C0017178" disease_type="Disease or Syndrome" abbrv="">gastrointestinal diseases</z:e> and healthy donors (p&lt;0.001) </plain></SENT>
<SENT sid="5" pm="."><plain>Interestingly, aberrant RUNX3 methylation in serum DNA was associated with advanced stage (p=0.027) and lymph <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastasis</z:e> (p=0.032) in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESCC</z:e>, but not in GC and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>Furthermore, the combinational analysis of CEA, CA19-9 and RUNX3 methylation showed a higher sensitivity and no reduced diagnostic specificity than CEA and CA19-9 combination in the three <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: The serum RUNX3 promoter hypermethylation may be a promising biomarker for the early diagnosis of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESCC</z:e>, GC and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>, which was further confirmed by combining with CEA and CA19-9 </plain></SENT>
</text></document>